Autemtherapeutics

About Autemtherapeutics

Autem Therapeutics is a bioelectric technology company operating in the oncology sector, founded in 2022 by Frederico Costa and Michael Choukas, with headquarters in Hanover, New Hampshire. The company's inception was driven by an oncologist's mission to find new cancer treatments with fewer side effects. Michael Choukas serves as the CEO, bringing extensive experience from leadership roles at various healthcare companies, including ConcertAI and Vector Oncology. Frederico Costa, the Chief Scientific Officer, is a medical oncologist on the faculty at Hospital Sírio Libanês's Centro de Oncologia and a former fellow at Memorial Sloan-Kettering Cancer Center.

The company is focused on developing treatments for Hepatocellular Carcinoma (HCC) and other solid tumor cancers. Autem Therapeutics has developed a proprietary bioelectric platform, AutEMsys™, which is a non-invasive and non-toxic therapy. This system delivers personalized, low-level, amplitude-modulated electromagnetic (EM) frequencies to patients. The technology aims to disrupt the metabolic processes of cancer cells. For dividing cancer cells, it disrupts mitotic spindles to inhibit proliferation, while in non-dividing cells, it destabilizes microtubules to cut off their energy supply. This process is designed to shrink tumors, improve quality of life, and extend survival for patients with both early and advanced-stage cancers. The treatment can be used as a standalone therapy or in conjunction with existing treatments.

Autem Therapeutics has secured significant funding to advance its technology and clinical trials, raising a total of $11.5 million over two rounds. A key Series A-1 financing round in June 2022 brought in $10 million, led by Zentynel Frontier Investments, a venture capital fund specializing in biotech and life sciences. These funds are allocated for the next-generation AutEMsys™ technology, regulatory submissions in the US, Europe, and Latin America, and to initiate pivotal clinical trials. The company's AutEMsys™ therapy has received breakthrough designation from the U.S. Food and Drug Administration (FDA) for treating advanced HCC. The business model centers on the development and future commercialization of this medical device, serving cancer patients, healthcare providers, and health systems.